SIM0237 not checked
Jiangsu Simcere Pharmaceutical Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Several dose levels of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation”In the company’s words, NCT06186414 on ClinicalTrials.gov
- Main trialPhase 1
- “This is an open-label, multicenter phase 1 study to evaluate the safety, efficacy, and pharmacokinetics (PK) characteristics of SIM0237 alone or in combination with bacillus Calmette-Guerin (BCG) in participants with Non-Muscle-Invasive Bladder Cancer (NMIBC)”In the company’s words, NCT06186414 on ClinicalTrials.gov
Other drugs for Non-Muscle-Invasive Bladder Cancer (NMIBC)
- Cretostimogene GrenadenorepvecCG Oncology, Inc. · Phase 3
- Nogapendekin alfa inbakiceptImmunityBio · Phase 2/3
- NDV-01Relmada Therapeutics, Inc. · Phase 3
- TAR-210Johnson & Johnson (Janssen) · Phase 3
- TARA-002Protara Therapeutics · Phase 3
- Alpha1HHamlet Pharma AB · Phase 3
Coming up1
- Jan 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Jan 2027 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC | |
| Phase 1Terminated | 25 May 2024 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026